Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 26 Week Treatment, Randomized, Multi Center, Double Blind, Double Dummy, Parallel-Group Study to Assess the Safety of Indacaterol (300 and 600 microg o.d.) in Patients With Moderate to Severe Persistent Asthma, Using Salmeterol (50 microg b.i.d.) as an Active Control.

Next Previous
X
Search
Trial Profile

A 26 Week Treatment, Randomized, Multi Center, Double Blind, Double Dummy, Parallel-Group Study to Assess the Safety of Indacaterol (300 and 600 microg o.d.) in Patients With Moderate to Severe Persistent Asthma, Using Salmeterol (50 microg b.i.d.) as an Active Control.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Indacaterol (Primary) ; Salmeterol
  • Indications Asthma
  • Focus Adverse reactions; Registrational
  • Sponsors Novartis

    • Most Recent Events

    • 09 Jun 2012 Additional company (GlaxoSmithKline) added in association as reported by European Clinical Trials Database.
    • 22 Jul 2011 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
    • 22 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top